Sorafenib is the only chemotherapeutic agent currently approved for unresectable
hepatocellular carcinoma (HCC). However, poor response rates have been widely reported …

Sorafenib (SOR) is the first-line treatment for hepatocellular carcinoma (HCC). However, its
use is hindered by the recently expressed safety concerns. One approach for reducing SOR …

In hepatocellular carcinoma (HCC), sorafenib (Sora) efficacy is limited by primary and/or
acquired resistance. Emerging evidence shows that the inflammatory factor interleukin 6 (IL …

Sorafenib, a multikinase inhibitor, is the first-line agent for advanced liver cancer. Sorafenib
strongly inhibits both cell proliferation and tumour angiogenesis. However, the development …

Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies and deadliest
cancers in the world. Currently, sorafenib is the only drug that has been approved by the US …

Hepatocellular carcinoma (HCC) is among the most common and aggressive cancers
worldwide, and novel therapeutic strategies are urgently required to improve clinical …

Aims Hepatocellular carcinoma (HCC) is the most common liver malignancy, characterized
by dysregulation of multiple oncogenic signaling pathways, including the VEGF/PI3K/NF-κB …

Sorafenib resistance is one of the major factors affecting the prognosis of patients with
hepatocellular carcinoma (HCC). Increasing evidence has indicated that certain traditional …

Sorafenib is a first-line drug to treat advanced hepatocellular carcinoma (HCC), which can
prolong the median overall survival of patients by approximately 3 months. Phenformin is a …

SL1122-37 is a novel derivative of sorafenib that was characterized by introducing
trifluoromethyl on the 4-position of indazole. We aimed to evaluate the effects of SL1122-37 …